Package Leaflet: Information for the Patient
PREVYMIS 240mg film-coated tablets
PREVYMIS 480mg film-coated tablets
letermovir
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
PREVYMIS is a prescription antiviral medicine that contains the active substance letermovir.
PREVYMIS is a medicine for:
The medicine helps to prevent you from getting the disease caused by CMV (cytomegalovirus).
CMV is a virus. For most people, CMV does not cause any harm. However, if your immune system is weakened after receiving a stem cell or kidney transplant, you may be at high risk of getting sick from CMV.
Do not take PREVYMIS:
Do not take PREVYMIS if any of the above applies to you. If you are unsure, consult your doctor, pharmacist, or nurse before taking PREVYMIS.
If you are taking PREVYMIS with cyclosporine, do not take the following medicines:
Warnings and precautions
If you are also taking a medicine to treat high cholesterol (see list of medicines in the section "Other medicines and PREVYMIS"), you must inform your doctor immediately if you have unexplained muscle pain or weakness, especially if you are feeling unwell or have a fever. Then, it may be necessary to change your medicine or dose. For more information, see the leaflet for your other medicine.
Additional blood tests may be needed to monitor the following medicines:
Children and adolescents
PREVYMIS should not be used in children who weigh less than 5 kg who have received a stem cell transplant (bone marrow transplant) or in children who weigh less than 40 kg who have received a kidney transplant. This is because PREVYMIS has not been studied in these groups.
Other medicines and PREVYMIS
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because PREVYMIS may affect the way other medicines work and other medicines may affect the way PREVYMIS works. Your doctor or pharmacist will tell you if it is safe to take PREVYMIS with other medicines.
There are some medicines that you must not takewith PREVYMIS (see list in "Do not take PREVYMIS:").
There are some medicines that you must not takewith PREVYMIS and cyclosporine (see list in “If you are taking PREVYMIS with cyclosporine, do not take the following medicines:”).
Also, tell your doctor if you are taking any of the following medicines. This is because your doctor may need to change your medicines or change the dose of your medicines:
You can ask your doctor or pharmacist for a list of medicines that may interact with PREVYMIS.
Pregnancy
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. PREVYMIS should not be used during pregnancy. This is because PREVYMIS has not been studied during pregnancy and it is not known whether PREVYMIS could harm the baby during pregnancy.
Breast-feeding
If you are breast-feeding or plan to breast-feed, ask your doctor for advice before taking this medicine. Breast-feeding is not recommended while taking PREVYMIS. This is because it is not known whether PREVYMIS passes into breast milk and could pass to your baby.
Driving and using machines
PREVYMIS may have a minor influence on your ability to drive and use machines (see section 4 "Possible side effects" later). Some patients have reported fatigue (feeling very tired) or dizziness (feeling like you are spinning) during treatment with PREVYMIS. If you experience any of these effects, do not drive or use machines until the effect disappears.
PREVYMIS contains lactose
PREVYMIS contains lactose monohydrate. If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
PREVYMIS contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially "sodium-free".
Always take this medicine exactly as your doctor or pharmacist has told you. If you are unsure, check with your doctor or pharmacist.
How much to take
Your dose of PREVYMIS depends on your weight and whether you are also taking cyclosporine. Your doctor will tell you how many tablets to take.
The recommended oral doses of PREVYMIS are presented in Table 1 and Table 2.
Table 1: Recommended doses of PREVYMIS film-coated tablets without cyclosporine
Weight | PREVYMIS oral daily dose | Number of PREVYMIS tablets once daily |
30 kg and above | 480 mg | One 480 mg tablet or Two 240 mg tablets |
Between 15 kg and less than 30 kg | 240 mg | One 240 mg tablet |
Table 2: Recommended doses of PREVYMIS film-coated tablets with cyclosporine
Weight | PREVYMIS oral daily dose | Number of PREVYMIS tablets once daily |
30 kg and above | 240 mg | One 240 mg tablet |
Between 15 kg and less than 30 kg | 120 mg | See the leaflet for PREVYMIS granules for oral suspension |
How to take
If you take more PREVYMIS than you should
If you take more PREVYMIS than you should, contact your doctor immediately.
If you forget to take PREVYMIS
It is very important that you do not miss or skip any dose of PREVYMIS.
Do not stop taking PREVYMIS
Do not stop taking PREVYMIS without talking to your doctor first. Do not run out of PREVYMIS. This way, the medicine will be more effective in preventing you from getting sick with CMV after receiving a stem cell or kidney transplant.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Common:may affect up to 1 in 10 people
Uncommon:may affect up to 1 in 100 people
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions. Store in the original package to protect from moisture.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of PREVYMIS
The active ingredient is letermovir. Each film-coated tablet contains 240 mg of letermovir or 480 mg of letermovir.
The other ingredients are:
Tablet core
Microcrystalline cellulose (E460), sodium croscarmellose (E468), povidone (E1201), colloidal anhydrous silica (E551), magnesium stearate (E470b).
Film coating
Lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin, yellow iron oxide (E172), red iron oxide (only in 480 mg tablets) (E172), carnauba wax (E903). See section 2 "PREVYMIS contains lactose" and "PREVYMIS contains sodium".
Appearance and Packaging of the Product
PREVYMIS 240 mg film-coated tablet ("tablet") is presented as a yellow, oval-shaped tablet with "591" engraved on one side and the corporate logo on the other side. The tablet measures 16.5 mm in length and 8.5 mm in width.
PREVYMIS 480 mg film-coated tablet ("tablet") is presented as a pink, biconvex, oval-shaped tablet with "595" engraved on one side and the corporate logo on the other side. The tablet measures 21.2 mm in length and 10.3 mm in width.
The 28x1 tablets are packaged in a box containing unit-dose blister packs of polyamide/aluminum/PVC-aluminum (a total of 28 tablets).
Marketing Authorization Holder Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem Netherlands | Manufacturer Organon Heist bv Industriepark 30 2220 Heist-op-den-Berg Belgium Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem Netherlands |
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien MSD Belgium Tel: +32(0)27766211 dpoc_belux@msd.com | Lietuva UAB Merck Sharp & Dohme Tel: + 370 5 2780 247 dpoc_lithuania@msd.com |
Luxembourg/Luxemburg MSD Belgium Tél/Tel: +32(0)27766211 dpoc_belux@msd.com | |
Ceská republika Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 dpoc_czechslovak@merck.com | Magyarország MSD Pharma Hungary Kft. Tel.: +36 1 888 5300 hungary_msd@merck.com |
Danmark MSD Danmark ApS Tlf.: + 45 4482 4000 dkmail@msd.com | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com |
Deutschland MSD Sharp & Dohme GmbH Tel.: +49 (0) 89 20 300 4500 medinfo@msd.de | Nederland Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com |
Eesti Merck Sharp & Dohme OÜ Tel: +372 614 4200 dpoc.estonia@msd.com | Norge MSD (Norge) AS Tlf: +47 32 20 73 00 medinfo.norway@msd.com |
Ελλάδα MSD Α.Φ.Ε.Ε. Τηλ: +30 210 98 97 300 dpoc_greece@merck.com | Österreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 dpoc_austria@merck.com |
España Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 msd_info@msd.com | Polska MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 msdpolska@merck.com |
France MSD France Tél: + 33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 inform_pt@merck.com |
Hrvatska Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 croatia_info@merck.com | România Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 msdromania@merck.com |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfo_ireland@msd.com | Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 5204 201 msd.slovenia@merck.com |
Ísland Vistor ehf. Sími: + 354 535 7000 | Slovenská republika Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 dpoc_czechslovak@merck.com |
Italia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) dpoc.italy@msd.com | Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0)9 804 650 info@msd.fi |
Κύπρος Merck Sharp & Dohme Cyprus Limited Τηλ.: 800 00 673 (+357 22866700) cyprus_info@merck.com | Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@msd.com |
Latvija SIA Merck Sharp & Dohme Latvija Tel.: + 371 67025300 dpoc.latvia@msd.com |
Date of the Last Revision of this Leaflet:{MM/YYYY}.
Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu.